FY2021 · ended Sep 30, 2021 · Revenue $0, -100.0% YoY · Filed Dec 16, 2022
Edesa Biotech, Inc. (EDSA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
-100.0% vs prior year
Net income
$-7.19M
-16.5% vs prior year
Operating cash flow (TTM)
$-8.91M
-35.6% vs year-ago TTM
Free cash flow
$-6.64M
+46.0% vs prior year
EPS
$-0.57
Dividend per share
None
Shares outstanding
8.33M
+140.3% vs prior year
Net cash
$10.80M
FY 2025
Operating margin
-1946.7%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EDSA (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1540159
- Former names
- Stellar Biotechnologies, Inc. (until May 30, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$7.9M | -$7.0M | -$9.2M | -$18.4M | -$23.7M |
| Net income | -$7.2M | -$6.2M | -$8.4M | -$17.5M | -$13.3M |
| Operating cash flow | -$7.3M | -$4.9M | -$6.6M | -$12.3M | -$13.7M |
| Free cash flow | — | — | -$6.6M | -$12.3M | -$13.7M |
| Total assets | $13.5M | $3.8M | $8.9M | $11.6M | $14.6M |
| Total liabilities | — | $1.8M | $1.8M | $2.2M | $1.5M |
| Stockholders' equity | $12.5M | $2.0M | $7.0M | $9.4M | $13.1M |
| Cash and investments | $10.8M | $1.0M | $5.4M | $7.1M | $7.8M |
| Total debt | $0 | $19,867 | $94,487 | $18,975 | $99,320 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 20, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 11, 2026 | Jun 10, 2026 |
All 751 Edesa Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.